PALI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Palisade Bio Inc (PALI) is not a strong buy for a beginner investor with a long-term strategy at this time. While the stock has bullish moving averages and positive MACD, the lack of significant positive catalysts, weak financial performance, and no recent trading signals suggest holding off on investment until clearer opportunities arise.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram of 0.0314, and RSI_6 at 44.467, which is neutral. Key support and resistance levels are Pivot: 2.307, R1: 2.713, S1: 1.9, R2: 2.965, S2: 1.648. Pre-market price is $2.22 with a 2.30% increase.
Analysts have issued multiple Buy ratings with price targets ranging from $5 to $12, citing potential in PALI-2108 for ulcerative colitis and Crohn's disease. The stock is positioned in a large, validated commercial market.
EPS dropped significantly by -89.68% YoY. No recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, revenue remained at $0 with no growth. Net income improved to -$8.9M, up 166.12% YoY, but EPS dropped significantly to -0.16 (-89.68% YoY). Gross margin remains at 0.
Analysts are generally bullish with multiple Buy ratings and price targets between $5 and $12. They highlight the potential of PALI-2108 in addressing unmet needs in inflammatory bowel diseases, though some concerns exist about timing and mixed data in the drug class.
